Literature DB >> 10880794

SFEMG in ocular myasthenia gravis diagnosis.

L Padua1, E Stalberg, M LoMonaco, A Evoli, A Batocchi, P Tonali.   

Abstract

BACKGROUND AND
OBJECTIVE: In typical cases, the patient's history and clinical examination make it possible to diagnose ocular myasthenia gravis (OMG). But, in many cases a clear clinical picture is not present and OMG diagnosis is very difficult because gold diagnostic standard tests are not available. The diagnostic tests for OMG are usually unable to display a good sensitivity and specificity simultaneously. In this paper, we studied 86 cases submitted for suspected OMG.
METHODS: The patients were studied clinically and with various other tests used in OMG diagnosis (SFEMG, repetitive nerve stimulation, Ab anti AChR titration, tensilon test). RESULTS AND
CONCLUSION: SFEMG showed the highest sensitivity (100%) while Ab anti AChR showed the highest specificity (100%). To our knowledge this is the largest population of suspected OMG studied using most of the diagnostic parameters, reported in the literature.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10880794     DOI: 10.1016/s1388-2457(00)00307-2

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  21 in total

1.  In response to "current approach to seronegative myasthenia" by Z. Argov.

Authors:  Michal Haran
Journal:  J Neurol       Date:  2010-11-18       Impact factor: 4.849

2.  Evaluation of a scale of patient-reported outcomes for the assessment of myasthenia gravis patients in China.

Authors:  Feng-bin Liu; Xin-lin Chen; Li Guo; Xiao-bin Liu
Journal:  Chin J Integr Med       Date:  2012-02-27       Impact factor: 1.978

3.  Sensitivity and specificity of single-fibre EMG in the diagnosis of ocular myasthenia varies accordingly to clinical presentation.

Authors:  Maria Pia Giannoccaro; Vitantonio Di Stasi; Corrado Zanesini; Vincenzo Donadio; Patrizia Avoni; Rocco Liguori
Journal:  J Neurol       Date:  2019-11-16       Impact factor: 4.849

Review 4.  Clinical Evaluation of Blepharoptosis: Distinguishing Age-Related Ptosis from Masquerade Conditions.

Authors:  Michelle W Latting; Alison B Huggins; Douglas P Marx; Joseph N Giacometti
Journal:  Semin Plast Surg       Date:  2017-02       Impact factor: 2.314

5.  A genome-wide association study of myasthenia gravis.

Authors:  Alan E Renton; Hannah A Pliner; Carlo Provenzano; Amelia Evoli; Roberta Ricciardi; Michael A Nalls; Giuseppe Marangi; Yevgeniya Abramzon; Sampath Arepalli; Sean Chong; Dena G Hernandez; Janel O Johnson; Emanuela Bartoccioni; Flavia Scuderi; Michelangelo Maestri; J Raphael Gibbs; Edoardo Errichiello; Adriano Chiò; Gabriella Restagno; Mario Sabatelli; Mark Macek; Sonja W Scholz; Andrea Corse; Vinay Chaudhry; Michael Benatar; Richard J Barohn; April McVey; Mamatha Pasnoor; Mazen M Dimachkie; Julie Rowin; John Kissel; Miriam Freimer; Henry J Kaminski; Donald B Sanders; Bernadette Lipscomb; Janice M Massey; Manisha Chopra; James F Howard; Wilma J Koopman; Michael W Nicolle; Robert M Pascuzzi; Alan Pestronk; Charlie Wulf; Julaine Florence; Derrick Blackmore; Aimee Soloway; Zaeem Siddiqi; Srikanth Muppidi; Gil Wolfe; David Richman; Michelle M Mezei; Theresa Jiwa; Joel Oger; Daniel B Drachman; Bryan J Traynor
Journal:  JAMA Neurol       Date:  2015-04       Impact factor: 18.302

6.  Acute ophthalmoparesis in the anti-GQ1b antibody syndrome: electrophysiological evidence of neuromuscular transmission defect in the orbicularis oculi.

Authors:  Y L Lo; L L Chan; A Pan; P Ratnagopal
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

7.  Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations.

Authors:  Michael F Seldin; Omar K Alkhairy; Annette T Lee; Janine A Lamb; Jon Sussman; Ritva Pirskanen-Matell; Fredrik Piehl; Jan J G M Verschuuren; Anna Kostera-Pruszczyk; Piotr Szczudlik; David McKee; Angelina H Maniaol; Hanne F Harbo; Benedicte A Lie; Arthur Melms; Henri-Jean Garchon; Nicholas Willcox; Peter K Gregersen; Lennart Hammarstrom
Journal:  Mol Med       Date:  2015-11-10       Impact factor: 6.354

8.  Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic.

Authors:  Ayşın Kısabay; Hüseyin Nezih Özdemir; Figen Gökçay; Neşe Çelebisoy
Journal:  Acta Neurol Belg       Date:  2021-02-05       Impact factor: 2.396

9.  Prognostic factors for conversion to generalization in ocular myasthenia gravis.

Authors:  Juthamat Witthayaweerasak; Narisa Rattanalert; Nipat Aui-Aree
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

Review 10.  Contribution of Single-Fiber Evaluation on Monitoring Outcomes Following Injection of Botulinum Toxin-A: A Narrative Review of the Literature.

Authors:  Hélène Moron; Corine Gagnard-Landra; David Guiraud; Arnaud Dupeyron
Journal:  Toxins (Basel)       Date:  2021-05-17       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.